Allergan NYSE: AGN is trying to expand the use of its anti-wrinkle drug, Botox, but the Food and Drug Administration threw a wrinkle into its plan yesterday by turning down Allergan’s application to market Botox for upper limb spasticity — a disorder that causes muscles to tighten. Getting a complete response letter is rarely a good thing, but it wasn’t all bad news for Allergan.

Read full story via Fool.com